HEBP2

Summary

HEBP2 (heme binding protein 2, HGNC:15716) is a protein-coding gene on chromosome 6q24.1, encoding Heme-binding protein 2 (Q9Y5Z4). Can promote mitochondrial permeability transition and facilitate necrotic cell death under different types of stress conditions.

The protein encoded by this gene is found predominately in the cytoplasm, where it plays a role in the collapse of mitochondrial membrane potential (MMP) prior to necrotic cell death. The encoded protein enhances outer and inner mitochondrial membrane permeabilization, especially under conditions of oxidative stress.

Source: NCBI Gene 23593 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 39 total
• MANE Select transcript: NM_014320

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15716
Approved symbol	HEBP2
Name	heme binding protein 2
Location	6q24.1
Locus type	gene with protein product
Status	Approved
Aliases	SOUL
Ensembl gene	ENSG00000051620
Ensembl biotype	protein_coding
OMIM	605825
Entrez	23593

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 nonsense_mediated_decay

ENST00000367697, ENST00000448741, ENST00000453452, ENST00000607197, ENST00000858693

RefSeq mRNA: 3 — MANE Select: NM_014320 NM_001326380, NM_001326381, NM_014320

CCDS: CCDS5191, CCDS87448

Canonical transcript exons

ENST00000607197 — 4 exons

Exon	Start	End
ENSE00000764663	138405971	138406151
ENSE00000798945	138404223	138404597
ENSE00001266936	138405145	138405280
ENSE00003698532	138412880	138422197

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 70.5852 / max 626.1941, expressed in 1822 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
70107	67.9603	1822
70109	1.3126	673
70112	0.6618	360
70108	0.6505	344

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	99.10	gold quality
amniotic fluid	UBERON:0000173	99.07	gold quality
cervix squamous epithelium	UBERON:0006922	98.87	gold quality
lower esophagus mucosa	UBERON:0035834	98.78	gold quality
cervix epithelium	UBERON:0004801	98.48	gold quality
gingiva	UBERON:0001828	98.27	gold quality
gingival epithelium	UBERON:0001949	98.03	gold quality
mammalian vulva	UBERON:0000997	97.92	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.85	gold quality
upper leg skin	UBERON:0004262	97.84	gold quality
heart right ventricle	UBERON:0002080	97.79	gold quality
adipose tissue	UBERON:0001013	97.78	gold quality
tongue squamous epithelium	UBERON:0006919	97.78	gold quality
oral cavity	UBERON:0000167	97.75	gold quality
esophagus mucosa	UBERON:0002469	97.74	gold quality
endometrium epithelium	UBERON:0004811	97.74	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.70	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.69	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.60	gold quality
omental fat pad	UBERON:0010414	97.60	gold quality
peritoneum	UBERON:0002358	97.56	gold quality
skin of hip	UBERON:0001554	97.52	gold quality
biceps brachii	UBERON:0001507	97.49	gold quality
connective tissue	UBERON:0002384	97.46	gold quality
triceps brachii	UBERON:0001509	97.40	gold quality
gluteal muscle	UBERON:0002000	97.35	gold quality
subcutaneous adipose tissue	UBERON:0002190	97.32	gold quality
squamous epithelium	UBERON:0006914	97.11	gold quality
nasal cavity mucosa	UBERON:0001826	97.09	gold quality
epithelium of esophagus	UBERON:0001976	97.03	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	212.63
E-MTAB-6524	no	229.34
E-MTAB-4850	no	210.47
E-MTAB-7037	no	124.60
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF

Literature-anchored findings (GeneRIF, showing 5)

• SOUL promotes necrotic cell death by inducing mitochondrial permeability transition (PMID:17098234)
• preliminary X ray structure (PMID:19574650)
• SOUL can be a novel member of the BH3 domain-only proteins that cannot induce cell death alone but can facilitate both outer and inner mitochondrial membrane permeabilization and predominantly necrotic cell death in oxidative stress. (PMID:19901022)
• There are important structural differences in the BH3 domain in the intact SOUL molecule and the same sequence bound to Bcl-xL. (PMID:21639858)
• The gene copy numbers and mRNA levels for both ALG-2 and HEBP2 are significantly upregulated in breast and lung cancer. Coexpression of ALG-2 and HEBP2 markedly increases the cytoplasmic pool of ALG-2 and alters the subcellular distribution of HEBP2. Abnormalities in the ALG-2/HEBP2 interaction impairs spindle orientation and positioning during mitosis. (PMID:28004381)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	hebp2	ENSDARG00000042630
mus_musculus	Hebp2	ENSMUSG00000019853
rattus_norvegicus	Hebp2	ENSRNOG00000053735

Paralogs (1): HEBP1 (ENSG00000013583)

Protein

Protein identifiers

Heme-binding protein 2 — Q9Y5Z4 (reviewed: Q9Y5Z4)

Alternative names: Placental protein 23, Protein SOUL

All UniProt accessions (4): C9IZA0, Q9Y5Z4, H7C0N7, Q5THN1

UniProt curated annotations — full annotation on UniProt →

Function. Can promote mitochondrial permeability transition and facilitate necrotic cell death under different types of stress conditions.

Subunit / interactions. Monomer. Interacts with LRPPRC. May interact with BCL2L1; an interaction with BCL2L1 was observed using a peptide, but not with the full-length protein. The full-length protein would have to undergo a major conformation change for the interaction to occur. Interacts with PDCD6.

Subcellular location. Cytoplasm. Mitochondrion.

Tissue specificity. Detected in placenta.

Domain organisation. Forms a distorted beta-barrel structure, with two helices that are packed against the outer surface of the barrel.

Similarity. Belongs to the HEBP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y5Z4-1	1	yes
Q9Y5Z4-2	2

RefSeq proteins (3): NP_001313309, NP_001313310, NP_055135* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006917	SOUL_heme-bd	Family
IPR011256	Reg_factor_effector_dom_sf	Homologous_superfamily

Pfam: PF04832

UniProt features (24 total): strand 12, helix 4, modified residue 2, sequence variant 2, initiator methionine 1, chain 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
3R8J	X-RAY DIFFRACTION	1.6
3R85	X-RAY DIFFRACTION	1.95
5GQQ	X-RAY DIFFRACTION	2.2
3R8K	X-RAY DIFFRACTION	2.85
4AYZ	X-RAY DIFFRACTION	3.5
4B0Y	X-RAY DIFFRACTION	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5Z4-F1	86.37	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 181

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 165 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, FREAC2_01, REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_SECRETORY_GRANULE, FOXO4_01, AP2_Q3, GGGTGGRR_PAX4_03, INGRAM_SHH_TARGETS_UP, RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, PTF1BETA_Q6, VANTVEER_BREAST_CANCER_ESR1_DN, CCCNNGGGAR_OLF1_01

GO Biological Process (0):

GO Molecular Function (2): heme binding (GO:0020037), protein binding (GO:0005515)

GO Cellular Component (5): extracellular region (GO:0005576), cytoplasm (GO:0005737), mitochondrion (GO:0005739), azurophil granule lumen (GO:0035578), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
tetrapyrrole binding	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
intracellular membrane-bounded organelle	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1
extracellular vesicle	1

Protein interactions and networks

STRING

346 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HEBP2	CECR2	Q9BXF3	914
HEBP2	UXT	Q9UBK9	864
HEBP2	MAP1S	Q66K74	858
HEBP2	LRPPRC	P42704	849
HEBP2	TCEAL1	Q15170	713
HEBP2	ENDOU	P21128	641
HEBP2	TPK1	Q9H3S4	621
HEBP2	LGALS13	Q9UHV8	601
HEBP2	NUTF2	P13662	597
HEBP2	PLIN3	O60664	517
HEBP2	STMN1	P16949	507
HEBP2	DUS4L	O95620	506
HEBP2	PPP6C	O00743	506
HEBP2	IFT25	Q9Y547	474
HEBP2	EPN3	Q9H201	460

IntAct

22 interactions, top by confidence:

A	B	Type	Score
LARP4B	RACK1	psi-mi:“MI:0914”(association)	0.880
PEF1	KLHL12	psi-mi:“MI:0914”(association)	0.880
HEBP2	PDCD6	psi-mi:“MI:0915”(physical association)	0.840
PDCD6	HEBP2	psi-mi:“MI:0915”(physical association)	0.840
PDCD6	SEC31A	psi-mi:“MI:0914”(association)	0.740
CD27	TCAF2	psi-mi:“MI:0914”(association)	0.640
PLEKHF2	HEBP2	psi-mi:“MI:0915”(physical association)	0.560
HEBP2	HNRNPD	psi-mi:“MI:0915”(physical association)	0.400
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350
	CLIC1	psi-mi:“MI:0914”(association)	0.350
GAB2	UBA6	psi-mi:“MI:0914”(association)	0.350
VENTX	UBA6	psi-mi:“MI:0914”(association)	0.350
HEBP2	PDCD6	psi-mi:“MI:0915”(physical association)	0.000
PLEKHF2	HEBP2	psi-mi:“MI:0915”(physical association)	0.000
HEBP2	LAMTOR5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (24): HEBP2 (Two-hybrid), HEBP2 (Affinity Capture-RNA), HEBP2 (Affinity Capture-RNA), HEBP2 (Two-hybrid), HEBP2 (Affinity Capture-RNA), HEBP2 (Affinity Capture-MS), PLEKHF2 (Two-hybrid), PDCD6 (Two-hybrid), HEBP2 (Proximity Label-MS), HEBP2 (Two-hybrid), HEBP2 (Affinity Capture-MS), HEBP2 (Two-hybrid), HEBP2 (Affinity Capture-MS), HEBP2 (Co-fractionation), HEBP2 (Two-hybrid)

ESM2 similar proteins: A0A0D1CD96, A2XNR6, A2YQ56, A6R2K7, O16216, O35501, P12076, P20583, P20973, P22774, P26882, P29845, P31251, P38646, P38647, P48721, P49588, P51660, P86233, P93648, Q01899, Q02028, Q08276, Q08752, Q148C9, Q29LW1, Q3ZCH0, Q43207, Q5ISC6, Q5R511, Q5RC02, Q5ZM98, Q5ZMB2, Q69UZ3, Q6DGG0, Q6DJ66, Q6NU05, Q75LJ3, Q8BGQ7, Q8GUM2

Diamond homologs: Q148C9, Q5ISC6, Q5ZMB2, Q6DJ66, Q6NU05, Q9NRV9, Q9R257, Q9Y5Z4, Q9WU63

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

663 predictions. Top by Δscore:

Variant	Effect	Δscore
6:138404593:CCCAG:C	donor_loss	1.0000
6:138404594:CCAGG:C	donor_loss	1.0000
6:138404595:CAGGT:C	donor_loss	1.0000
6:138404598:G:C	donor_loss	1.0000
6:138404599:T:G	donor_loss	1.0000
6:138405143:A:AG	acceptor_gain	1.0000
6:138405143:AGCCC:A	acceptor_gain	1.0000
6:138405144:G:GG	acceptor_gain	1.0000
6:138405144:GCCCG:G	acceptor_gain	1.0000
6:138405267:C:T	donor_gain	1.0000
6:138405276:GAAAG:G	donor_gain	1.0000
6:138405279:AGG:A	donor_loss	1.0000
6:138405281:G:T	donor_loss	1.0000
6:138405282:T:G	donor_loss	1.0000
6:138405963:T:G	acceptor_gain	1.0000
6:138405967:ACAG:A	acceptor_loss	1.0000
6:138405968:CA:C	acceptor_loss	1.0000
6:138405968:CAG:C	acceptor_gain	1.0000
6:138405969:A:AG	acceptor_gain	1.0000
6:138405969:A:AT	acceptor_loss	1.0000
6:138405969:AGA:A	acceptor_gain	1.0000
6:138405970:G:GA	acceptor_gain	1.0000
6:138405970:GA:G	acceptor_gain	1.0000
6:138405970:GAG:G	acceptor_gain	1.0000
6:138405970:GAGAT:G	acceptor_gain	1.0000
6:138406147:GTACG:G	donor_gain	1.0000
6:138406150:CGG:C	donor_loss	1.0000
6:138406151:GGT:G	donor_loss	1.0000
6:138406152:G:A	donor_loss	1.0000
6:138406152:G:GG	donor_gain	1.0000

AlphaMissense

1353 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:138412884:T:C	F142L	0.991
6:138412886:C:A	F142L	0.991
6:138412886:C:G	F142L	0.991
6:138405184:T:A	W48R	0.989
6:138405184:T:C	W48R	0.989
6:138405164:G:C	R41P	0.988
6:138405186:G:C	W48C	0.987
6:138405186:G:T	W48C	0.987
6:138406054:T:C	S108P	0.987
6:138412924:T:C	L155P	0.983
6:138413041:T:C	L194S	0.981
6:138412965:T:C	F169L	0.980
6:138412967:C:A	F169L	0.980
6:138412967:C:G	F169L	0.980
6:138413037:T:A	W193R	0.980
6:138413037:T:C	W193R	0.980
6:138412945:T:C	L162S	0.977
6:138406151:G:C	R140P	0.975
6:138406144:T:C	F138L	0.974
6:138406146:T:A	F138L	0.974
6:138406146:T:G	F138L	0.974
6:138412989:G:C	A177P	0.974
6:138405188:T:A	V49D	0.973
6:138405273:C:A	N77K	0.973
6:138405273:C:G	N77K	0.973
6:138405248:T:C	L69P	0.971
6:138406058:T:C	L109P	0.971
6:138412933:T:C	L158S	0.971
6:138406142:T:A	V137E	0.967
6:138405995:C:A	P88Q	0.965

dbSNP variants (sampled 300 via entrez): RS1000101098 (6:138406375 A>G), RS1000138453 (6:138415358 G>A), RS1000475861 (6:138414195 C>G), RS1000490871 (6:138415587 A>G), RS1000548918 (6:138414361 C>T), RS1000701925 (6:138407870 C>T), RS1000753250 (6:138409476 C>G,T), RS1001090673 (6:138420443 G>A), RS1001202837 (6:138417028 G>A), RS1001355492 (6:138411072 C>G), RS1001390916 (6:138410291 A>G), RS1001566165 (6:138420759 G>A), RS1002147853 (6:138422108 G>A), RS1002160043 (6:138410475 C>T), RS1002196582 (6:138404597 G>A)

Disease associations

OMIM: gene MIM:605825 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
chloropicrin	increases expression	1
bisphenol B	increases expression	1
bisphenol AF	increases expression	1
Acetaminophen	decreases expression	1
Caffeine	affects phosphorylation	1
Dinitrochlorobenzene	affects binding	1
Furaldehyde	affects cotreatment, affects localization, increases expression	1
Isoflavones	decreases expression	1
Ivermectin	decreases expression	1
Potassium Dichromate	increases expression	1
Quercetin	increases expression	1
Sodium Chloride	affects cotreatment, affects localization, increases expression, decreases expression	1
Dihydrotestosterone	increases expression	1
Testosterone	decreases expression	1
Tretinoin	increases expression	1
Triclosan	decreases expression	1
Valproic Acid	increases expression	1
Cyclosporine	increases expression	1
Sodium Selenite	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer